Literature DB >> 15016627

Reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts.

Yutaka Kitagawa1, Daisuke Yamashita, Haruo Ito, Miyako Takaki.   

Abstract

The aim of the present study was to evaluate specifically left ventricular (LV) function in rat hearts as they transition from the normal to hypertrophic state and back to normal. Either isoproterenol (1.2 and 2.4 mg.kg(-1).day(-1) for 3 days; Iso group) or vehicle (saline 24 microl.day(-1) for 3 days; Sa group) was infused by subcutaneous implantation of an osmotic minipump. After verifying the development of cardiac hypertrophy, we recorded continuous LV pressure-volume (P-V) loops of in situ ejecting hypertrophied rat hearts. The curved LV end-systolic P-V relation (ESPVR) and systolic P-V area (PVA) were obtained from a series of LV P-V loops in the Sa and Iso groups 1 h or 2 days after the removal of the osmotic minipump. PVA at midrange LV volume (PVA(mLVV)) was taken as a good index for LV work capability (13, 15, 20, 21). However, in rat hearts during remodeling, whether PVA(mLVV) is a good index for LV work capability has not been determined yet. In the present study, in contrast to unchanged end-systolic pressure at midrange LV volume, PVA(mLVV) was significantly decreased by isoproterenol treatment relative to saline; however, these measurements were the same 2 days after pump removal. Simultaneous treatment with a beta(1)-blocker, metoprolol (24 mg.kg(-1).day(-1)), blocked the formation of cardiac hypertrophy and thus PVA(mLVV) did not decrease. The reversible changes in PVA(mLVV) reflect precisely the changes in LV work capability in isoproterenol-induced hypertrophied rat hearts mediated by beta(1)-receptors. These results indicate that the present approach may be an appropriate strategy for evaluating the effects of antihypertrophic and antifibrotic modalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016627     DOI: 10.1152/ajpheart.00073.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Regression from pathological hypertrophy in mice is sexually dimorphic and stimulus specific.

Authors:  Deanna L Muehleman; Claudia Crocini; Alison R Swearingen; Christopher D Ozeroff; Leslie A Leinwand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-18       Impact factor: 4.733

2.  A new calpain inhibitor protects left ventricular dysfunction induced by mild ischemia-reperfusion in in situ rat hearts.

Authors:  D Takeshita; M Tanaka; S Mitsuyama; Y Yoshikawa; G-X Zhang; K Obata; H Ito; S Taniguchi; Miyako Takaki
Journal:  J Physiol Sci       Date:  2012-12-16       Impact factor: 2.781

3.  Increased O2 consumption in excitation-contraction coupling in hypertrophied rat heart slices related to increased Na+ -Ca2+ exchange activity.

Authors:  Juichiro Shimizu; Daisuke Yamashita; Hiromi Misawa; Kiyoe Tohne; Satoshi Matsuoka; Bongju Kim; Ayako Takeuchi; Chikako Nakajima-Takenaka; Miyako Takaki
Journal:  J Physiol Sci       Date:  2008-12-11       Impact factor: 2.781

Review 4.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

5.  Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'.

Authors:  Stefanie Maria Werhahn; Julia S Kreusser; Marco Hagenmüller; Jan Beckendorf; Nathalie Diemert; Sophia Hoffmann; Jobst-Hendrik Schultz; Johannes Backs; Matthias Dewenter
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

6.  Assessing structural and functional responses of murine hearts to acute and sustained β-adrenergic stimulation in vivo.

Authors:  Sarah-Lena Puhl; Kate L Weeks; Antonella Ranieri; Metin Avkiran
Journal:  J Pharmacol Toxicol Methods       Date:  2016-02-04       Impact factor: 1.950

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.